The Swiss flavours and fragrance maker on Thursday cut its five-year organic sales growth target to 4 to 5 percent from its previous target of 4.5 to 5.5 percent. The Geneva-based firm said it would target 12 to 17 percent free cash flow as a percentage of sales by 2020, from the 14 to 16 percent target set for 2015.
The Swiss drugmaker says a combination of its Cotellic and Zelboraf medicines were approved in Switzerland for the treatment of patients with advanced melanoma.
Also read: Factors to watch on Jan 12
13:48 Wells Fargo Profit Falls 5.4% as Mortgage Revenue Declines23
12:08 Bank of America Profit Rises 43% on Trading Gains, Cost Cuts22
12:02 Bank of America tops earnings forecast, predicts 'significant increase' in net interest income20
10:27 India's Tata Consultancy third-quarter net up 10.9 percent, beats estimates20